Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colistin vs Lactulose for Secondary Prophylaxis of Hepatic Encephalopathy
NCT05279586Phase 1Unknown
- Start
- Mar 2022
- Primary completion
- Feb 2023
- Modality
- Peptides
01
Overview
Phase 1, randomised, open-label trial of colistin in hepatic encephalopathy (HE). Primary endpoint: Development of overt hepatic encephalopathy at 6 months. Status: unknown.
02
Drugs
colistin
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT05279586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05279586.